Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 11:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 178 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Eosinophilic Esophagitis Clear all
Completed Phase 2 Interventional Results available

Topical Steroid Treatment for Eosinophilic Esophagitis

NCT00275561
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Fluticasone, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 8, 2012 · Synced Oct 9, 2026, 11:55 AM EDT
Terminated Phase 3 Interventional Results available

Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)

NCT03245840
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Budesonide oral suspension
Drug
Lead sponsor
Shire
Industry
Eligibility
11 Years to 55 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 9, 2026, 11:55 AM EDT
Recruiting Not applicable Interventional

The Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States

NCT07027826
View directory record Official record
Conditions
Dysphagia, Eosinophilic Esophagitis
Interventions
Esophageal string test
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 9, 2026, 11:55 AM EDT
Completed Not applicable Interventional

Sponge and Eosinophil Peroxidase (EPO) Staining

NCT03078023
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
swallowed sponge device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 9, 2026, 11:55 AM EDT
Completed Phase 2 Interventional

Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis

NCT00123656
View directory record Official record
Conditions
Esophagitis
Interventions
esomeprazole, fluticasone
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 16, 2008 · Synced Oct 9, 2026, 11:55 AM EDT
Terminated Not applicable Interventional Results available

Cytosponge Protocol IRB 11-006429

NCT01585103
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Cytosponge
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Oct 9, 2026, 11:55 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial

NCT05083312
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet
Drug
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
12 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 9, 2026, 11:55 AM EDT
Enrolling by invitation Early Phase 1 Interventional

Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.

NCT07358234
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT], budesonide oral suspension
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 9, 2026, 11:55 AM EDT
Withdrawn Phase 3 Interventional

A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis

NCT05152563
View directory record Official record
Conditions
Eosinophilic Gastritis, Eosinophilic Duodenitis
Interventions
AK002, Placebo
Drug · Other
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
76
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 9, 2026, 11:55 AM EDT
Completed No phase listed Observational

a4b7 Integrin in Eosinophilic Esophagitis

NCT02546219
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Eosinophil isolation and characterization.
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 9, 2026, 11:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mucosal Impedance in Pediatric Population

NCT02320981
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Eosinophilic Esophagitis (EoE), Functional Dyspepsia
Interventions
Standard of Care esophagogastroduodenoscopy (EGD) with measurement of mucosal impedance
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
1 Year to 18 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 9, 2026, 11:55 AM EDT
Terminated No phase listed Observational

Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders

NCT00557895
View directory record Official record
Conditions
Allergy, Asthma, Allergic Rhinitis, Mastocytosis, Atopic Dermatitis, Food Allergy
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 80 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 9, 2026, 11:55 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Inflammatory Mediators as Potential Non-Invasive Biomarkers in Subjects With Eosinophilic Esophagitis

NCT03822325
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Year to 18 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2027
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 9, 2026, 11:55 AM EDT
Terminated Phase 2 Interventional Results available

Eosinophilic Esophagitis Clinical Therapy Comparison Trial

NCT01821898
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Oral Budesonide, Elimination diet
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 9, 2026, 11:55 AM EDT
Completed No phase listed Observational

Characteristics of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort

NCT02897271
View directory record Official record
Conditions
Eosinophilic Esophagitis, Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Colitis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
6
States / cities
Little Rock, Arkansas • Denver, Colorado • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 9, 2026, 11:55 AM EDT
Completed Not applicable Interventional Results available

Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET)

NCT02722148
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 9, 2026, 11:55 AM EDT
Completed Phase 2 Interventional

Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome

NCT00017862
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
SCH55700
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 9, 2026, 11:55 AM EDT
Withdrawn Not applicable Interventional

EoE Food Desensitization

NCT02881372
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Oral food desensitization
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
3 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 9, 2026, 11:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mucosal Impedance Balloon in Diagnosis and Treatment of Eosinophilic Esophagitis (EoE)

NCT02995395
View directory record Official record
Conditions
Eosinophilic Esophagitis, Healthy
Interventions
Mucosal Impedance Balloon catheter
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 9, 2026, 11:55 AM EDT
Completed Phase 4 Interventional Results available

Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis

NCT02371941
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
oral cromolyn sodium, Placebo
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
2 Years to 18 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 9, 2026, 11:55 AM EDT
Completed Phase 2 Interventional Results available

Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD

NCT01808196
View directory record Official record
Conditions
Eosinophilic Esophagitis, Connective Tissue Disorders
Interventions
Losartan Potassium
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 9, 2026, 11:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Esophageal Clearance Times of Oral Budesonide Preparations

NCT02125851
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Xanthan Gum, Honey
Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Oct 9, 2026, 11:55 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis

NCT04322708
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Placebo, lirentelimab (AK002)
Other · Drug
Lead sponsor
Allakos Inc.
Industry
Eligibility
12 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
73
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 9, 2026, 11:55 AM EDT
Completed No phase listed Observational

Nasal Nitric Oxide Levels in Eosinophilic Esophagitis (EoE)

NCT01929824
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Oral Nitric Oxide testing
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 9, 2026, 11:55 AM EDT